Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy
|ClinicalTrials.gov Identifier: NCT00475527|
Recruitment Status : Withdrawn (problem of accrual)
First Posted : May 21, 2007
Last Update Posted : August 20, 2015
Iron deficiency anemia (IDA) is a major health problem in children, effecting up to 20% of young children. Helicobacter pylori (HP) infection is also reported to be prevalent in children. Several large epidemiologic studies support an association between HP infection and lower iron stores. Other small studies suggest improvement in anemia following HP treatment.
We assume that the prevalence of HP infection in Israeli children diagnosed with IDA is high and that that adding therapy for HP in those children will improve the response to iron deficiency.
|Condition or disease||Intervention/treatment||Phase|
|Anemia, Iron-Deficiency Helicobacter Pylori||Drug: omeprazole,clarithromycin,amoxicillin (or metronidazole)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
No Intervention: iron only
Only iron therapy
Experimental: iron + HP therapy
Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
|Drug: omeprazole,clarithromycin,amoxicillin (or metronidazole)|
- To compare the raise in hemoglobin level between baseline and eight weeks later in Fe-supplemented and HP-positive children treated for HP infection and Fe-supplemented HP-positive children not treated for HP. [ Time Frame: two years ]
- 1. To determine the prevalence of HP infection in children with IDA in Israel, 2. To compare the demographic, clinical and laboratory findings between children diagnosed with IDA with/without HP infection. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00475527
|Hadassah Medical Organization|
|Principal Investigator:||Shoshana Revel-Vilk, MD||Hadassah Medical Center|